Literature DB >> 8260265

Retinoic acid and interferon combination studies in human cancer.

S M Lippman1, B S Glisson, J J Kavanagh, R Lotan, W K Hong, M Paredes-Espinoza, W N Hittelman, E E Holdener, I H Krakoff.   

Abstract

Retinoic acid and interferon-alpha have limited single-agent activity in advanced cancer. Cell culture data indicate that in combination these agents have enhanced activity (modulating growth and differentiation) in a number of malignant cell types. Recent clinical work in advanced squamous cell carcinoma reports major activity with this regimen. This paper reviews the preclinical and clinical data testing retinoic acid in combination with interferons and presents recent work integrating these agents with radiotherapy in locally advanced cervical cancer.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8260265     DOI： 10.1016/0959-8049(93)90618-p

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  3 in total

1.  Phase II study of cisplatin, 5-fluorouracil and interferon-alpha in recurrent carcinoma of the cervix.

Authors:  C Gonzales-de Léon; S M Lippman; A P Kudelka; C L Edwards; J J Kavanagh
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

2.  Low-dose retinoic acid enhances in vitro invasiveness of human oral squamous-cell-carcinoma cell lines.

Authors:  D Uchida; H Kawamata; K Nakashiro; F Omotehara; S Hino; M O Hoque; N M Begum; H Yoshida; M Sato; T Fujimori
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

Review 3.  Molecular mechanisms and therapeutic effects of different vitamins and minerals in COVID-19 patients.

Authors:  Mohsen Karami Fath; Malihe Naderi; Hosna Hamzavi; Mahmoud Ganji; Shima Shabani; Faezeh Noorabad Ghahroodi; Bahman Khalesi; Navid Pourzardosht; Zahra Sadat Hashemi; Saeed Khalili
Journal:  J Trace Elem Med Biol       Date:  2022-07-20       Impact factor: 3.995
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.